In this study, the median PFS was 25.8 months and OS was also prolonged, demonstrating the clinical benefit of obinutuzumab.74,351 As well, tafasitamab (anti-CD19 mAb) is also approved for the treatment of R/R DLBCL and FL as a novel agent.23,209,210,352,353 Some mAbs which has already been approved in autoimmune disease, such as alemtuzumab (anti-CD52 mAb) and ublituximab (anti-CD20 mAb), also expanded their indications to hematologic malignancies. The gene discussed is CD19; the disease is hematologic disorder.